Overview

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
George Albert Fisher
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Gemcitabine
Paclitaxel